Literature DB >> 16766226

Toll-like receptor 2-mediated human B cell differentiation.

Lisa M Ganley-Leal1, Xiuping Liu, Lee M Wetzler.   

Abstract

Human B cells likely have a major role in the adjuvant activity of Toll-like receptor (TLR) 9 agonists by enhancing innate and adaptive immune responses. As several TLR2 ligands are promising vaccine adjuvant candidates, our aim was to characterize the effects of TLR2 stimulation on human B cell activation and differentiation using cells derived from healthy peripheral blood (PB), spleen, and diseased tonsils. We found a subset of partially differentiated TLR2+ PB and splenic B cells which responds to TLR2 agonists by mediating events involved in germinal center formation, such as upregulating CD77 and secreting chemokines. Furthermore, we show that TLR2-activated monocytes induce B cells to secrete significant quantities of IgM. Finally, activated TLR2+ B cells from tonsils are induced to secrete IgM directly by TLR2 ligands. Thus, TLR2 is likely involved in specific B cell-mediated functions and may be a viable vaccine adjuvant target in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16766226     DOI: 10.1016/j.clim.2006.04.571

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  23 in total

Review 1.  Toll-like receptors--sentries in the B-cell response.

Authors:  Isabelle Bekeredjian-Ding; Gaetan Jego
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

Review 2.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

3.  Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.

Authors:  Noëlle Mistretta; Bruno Guy; Yves Bérard; François Dalençon; Olivia Fratantonio; Christophe Grégoire; Aurélie Lechevallier; Philippe Lhéritier; Laurent Revet; Monique Moreau; Jean Haensler; Bachra Rokbi
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

4.  CD23b isoform expression in human schistosomiasis identifies a novel subset of activated B cells.

Authors:  Daniel Onguru; YanMei Liang; Jennifer Elliot; Pauline Mwinzi; Lisa Ganley-Leal
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

Review 5.  B cells as under-appreciated mediators of non-auto-immune inflammatory disease.

Authors:  Barbara S Nikolajczyk
Journal:  Cytokine       Date:  2010-04-10       Impact factor: 3.861

6.  Toll-like receptors regulate B cell cytokine production in patients with diabetes.

Authors:  M Jagannathan; M McDonnell; Y Liang; H Hasturk; J Hetzel; D Rubin; A Kantarci; T E Van Dyke; L M Ganley-Leal; B S Nikolajczyk
Journal:  Diabetologia       Date:  2010-04-11       Impact factor: 10.122

7.  Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4.

Authors:  Silvina Coviello; Vera Wimmenauer; Fernando P Polack; Pablo M Irusta
Journal:  Hum Vaccin Immunother       Date:  2014-11-19       Impact factor: 3.452

8.  Toll-like receptor 2 gene polymorphisms, pulmonary tuberculosis, and natural killer cell counts.

Authors:  Yung-Che Chen; Chang-Chun Hsiao; Chung-Jen Chen; Chien-Hung Chin; Shih-Feng Liu; Chao-Chien Wu; Hock-Liew Eng; Tung-Ying Chao; Chia-Cheng Tsen; Yi-Hsi Wang; Meng-Chih Lin
Journal:  BMC Med Genet       Date:  2010-01-30       Impact factor: 2.103

Review 9.  The expression and functions of toll-like receptors in atherosclerosis.

Authors:  Jennifer E Cole; Ektoras Georgiou; Claudia Monaco
Journal:  Mediators Inflamm       Date:  2010-06-24       Impact factor: 4.711

Review 10.  Toll-like receptors and NOD-like receptors in rheumatic diseases.

Authors:  William J McCormack; Andrew E Parker; Luke A O'Neill
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.